Eling Pharmaceutical announced that the company decided to apply to the State Drug Administration to withdraw the “G201-Na capsule” drug clinical trial application for “assisted reproduction indications”. The company has received the “Notice of Termination of Application for Drug Registration” approved and issued by the State Drug Administration. G201-Na capsules are a class 1 new chemical drug independently developed by the company. It is a small-molecule gonadotropin-releasing hormone receptor antagonist. The company has previously obtained clinical trial approval for this drug as a “prostate cancer drug requiring androgen castration treatment” and “uterine fibroids.” Currently, these two clinical trials are ongoing normally. The withdrawal of the application is not a termination of this project. The company plans to re-submit the application for registration of clinical trials at an optional date after improving the relevant research. The withdrawal is not expected to have a significant impact on the company's current and future production, operation and performance.

Eling Pharmaceutical announced that the company decided to apply to the State Drug Administration to withdraw the “G201-Na capsule” drug clinical trial application for “assisted reproduction indications”. The company has received the “Notice of Termination of Application for Drug Registration” approved and issued by the State Drug Administration. G201-Na capsules are a class 1 new chemical drug independently developed by the company. It is a small-molecule gonadotropin-releasing hormone receptor antagonist. The company has previously obtained clinical trial approval for this drug as a “prostate cancer drug requiring androgen castration treatment” and “uterine fibroids.” Currently, these two clinical trials are ongoing normally. The withdrawal of the application is not a termination of this project. The company plans to re-submit the application for registration of clinical trials at an optional date after improving the relevant research. The withdrawal is not expected to have a significant impact on the company's current and future production, operation and performance.